Journal of Gastrointestinal Cancer

, Volume 43, Issue 2, pp 279–287 | Cite as

Expression of Cell Cycle Regulators P21 and P27 as Predictors of Disease Outcome in Colorectal Carcinoma

  • Jaudah Al-Maghrabi
  • Mahmoud Al-Ahwal
  • Abdelbaset Buhmeida
  • Kari Syrjänen
  • Abdulrahman Sibyani
  • Eman Emam
  • Ayman Ghanim
  • Mohmmad Al-Qahtani
Original Article



Recent studies suggest that aberrations in cell cycle checkpoint controllers are a common feature in human malignancies and predict prognosis independent of stage.


This study correlated two cell cycle regulators (p27 and p21) with clinical and pathological variables in colorectal cancer (CRC) patients to assess their role as prognostic factors.

Patients and Methods

A series of 65 CRC patients were analyzed for p27 and p21 expression in their tumors using immunohistochemistry.


Forty-six percent of tumors showed positive nuclear p27 expression, whereas 72% of cases were completely p21 negative. There were no significant correlations between p27 and p21 expression and gender, age, lymph node involvement, stage, and grade. However, p27 (but not p21) expression revealed highly significant correlation with tumor location (p < 0.01), depth of invasion (p < 0.03), and lympho-vascular invasion (p < 0.02). Tumors with high p27 expression showed a higher recurrence rate than tumors with no expression (p < 0.03). In Kaplan–Meier survival analysis, there was a significant (p = 0.046) difference in disease-free survival (DFS) between p27-positive and p27-negative tumors in favor of the latter. p21 did not show any predictive value of DFS (p < 0.7). Neither p27 nor p21 did predict disease-specific survival (DSS) in Kaplan–Meier analysis, but DSS time was much shorter for p27-positive tumors. In multivariate (Cox) model, p27 lost its value as independent predictor of DFS, and none of the covariates were independent predictors of DSS.


p27 expression seems to be more powerful than p21 expression in providing useful prognostic information in CRC, particularly in predicting the patients at high risk for recurrent disease. Larger cohort and longer follow-up are needed to fully elucidate the value of p27 (and p21) as independent predictors of disease outcome.


CRC p27 p21 IHC Disease outcome Adjuvant therapy 



The authors would like to offer special thanks to Ministry of High Education, Kingdom of Saudi Arabia.This work was supported by scientific chair for colorectal cancer, King Abdul-Aziz University, Jeddah, Saudi Arabia.


  1. 1.
    Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol. 2010;25 Suppl 1:S49–56.PubMedCrossRefGoogle Scholar
  2. 2.
    Al-Eid H, Arteh S. Cancer incidence report Saudi Arabia. 2005;1–99.Google Scholar
  3. 3.
    Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–94.PubMedGoogle Scholar
  4. 4.
    Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med. 2006;130:318–24.PubMedGoogle Scholar
  5. 5.
    Seicean R, Funariu G, Seicean A. Molecular prognostic factors in rectal cancer. Rom J Gastroenterol. 2004;13:223–31.PubMedGoogle Scholar
  6. 6.
    Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol. 2003;14:1026–38.PubMedCrossRefGoogle Scholar
  7. 7.
    Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699–731.PubMedCrossRefGoogle Scholar
  8. 8.
    Buhmeida A, Hilska M, Elzagheid A, Laato M, Collan Y, Syrjanen K, et al. DNA image cytometry predicts disease outcome in stage II colorectal carcinoma. Anticancer Res. 2009;29:99–106.PubMedGoogle Scholar
  9. 9.
    Macaluso M, Montanari M, Cinti C, Giordano A. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005;32:452–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776–89.PubMedCrossRefGoogle Scholar
  11. 11.
    Chetty R. p27 Protein and cancers of the gastrointestinal tract and liver: an overview. J Clin Gastroenterol. 2003;37:23–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001;3:91–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Hoos A, Nissan A, Stojadinovic A, Shia J, Hedvat CV, Leung DH, et al. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res. 2002;8:3841–9.PubMedGoogle Scholar
  17. 17.
    Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006;99:185–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998;17:337–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381–5.PubMedGoogle Scholar
  20. 20.
    Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F, et al. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol. 1996;179:248–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Pasz-Walczak G, Kordek R, Faflik M. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract. 2001;197:683–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kanavaros P, Stefanaki K, Vlachonikolis J, Eliopoulos G, Kakolyris S, Rontogianni D, et al. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol. 2000;15:445–53.PubMedGoogle Scholar
  23. 23.
    Bukholm IK, Nesland JM. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 2000;436:224–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Greene F, Page D, Fleming I. AJJC cancer staging manual. 6th ed. New York: Springer; 2002. p. 113–122.Google Scholar
  25. 25.
    Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J. 2003;33:119–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Wilkinson N, Scott-Conner CE. Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am. 2008;37:253–67. ix.PubMedCrossRefGoogle Scholar
  27. 27.
    Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99.PubMedCrossRefGoogle Scholar
  28. 28.
    Heimann TM, Cohen RD, Szporn A, Gil J. Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Dis Colon Rectum. 1991;34:449–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Barderas R, Babel I, Casal JI. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl. 2010;4:159–78.PubMedCrossRefGoogle Scholar
  30. 30.
    Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010;134:478–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Palmqvist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol. 1999;188:18–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Cariou S, Catzavelos C, Slingerland JM. Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. Breast Cancer Res Treat. 1998;52:29–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Zhang H, Sun XF. Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. Int J Oncol. 2001;19:49–52.PubMedGoogle Scholar
  34. 34.
    Bendardaf R, Buhmeida A, Ristamaki R, Syrjanen K, Pyrhonen S. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol. 2007;42:1473–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113:779–88.PubMedGoogle Scholar
  36. 36.
    Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, et al. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol. 2000;95:2953–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Chen L, Yuan D, Wang GL, Wang Y, Wu YY, Zhu J. Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma. J Korean Med Sci. 2010;25:1438–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Lim YJ, Kim YH, Ahn GH, Chun HK, Jang WY, Lee JH, et al. Cyclin E, p27 and mutant p53 do not predict the prognosis in AJCC stage II colorectal carcinomas. Korean J Gastroenterol. 2004;44:314–20.PubMedGoogle Scholar
  41. 41.
    Cohen T, Prus D, Shia J, Abu-Wasel B, Pinto MG, Freund HR, et al. Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol. 2008;97:416–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Roa EI, Lantadilla HS, Ibacache SG, de Aretxabala UX. p53 and p27 gene expression in subserosal gallbladder carcinoma. Rev Med Chil. 2009;137:1017–22.PubMedGoogle Scholar
  43. 43.
    Wiksten JP, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology. 2002;63:180–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Kravtsov VG, Shakhmurov MG, Sukmanov OV, Zairat'iants OV, Shirin NI. Expression of cycline-dependent kinase p27 in the low differentiated gastric adenocarcinoma. Arkh Patol. 2006;68:14–6.PubMedGoogle Scholar
  45. 45.
    Fan JW, Fan PX, Wang Y, Zhang XQ. Relationship between expression of p27 and DNA ploidy in colorectal carcinoma. Ai Zheng. 2002;21:54–7.PubMedGoogle Scholar
  46. 46.
    Moore HG, Shia J, Klimstra DS, Ruo L, Mazumdar M, Schwartz GK, et al. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol. 2004;11:955–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jaudah Al-Maghrabi
    • 1
    • 3
  • Mahmoud Al-Ahwal
    • 2
  • Abdelbaset Buhmeida
    • 3
  • Kari Syrjänen
    • 4
  • Abdulrahman Sibyani
    • 5
  • Eman Emam
    • 1
  • Ayman Ghanim
    • 1
  • Mohmmad Al-Qahtani
    • 3
  1. 1.Department of PathologyKing Abdul-Aziz UniversityJeddahSaudi Arabia
  2. 2.Department of MedicineKing Abdul-Aziz UniversityJeddahSaudi Arabia
  3. 3.Center of Excellence in Genomic Medicine ResearchKing Abdul-Aziz UniversityJeddahSaudi Arabia
  4. 4.Department of Oncology and RadiotherapyTurku University HospitalTurkuFinland
  5. 5.Department of SurgeryKing Abdul-Aziz UniversityJeddahSaudi Arabia

Personalised recommendations